Responses
Psoriatic arthritis
Original research
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Compose a Response to This Article
Other responses
No responses have been published for this article.